Wednesday, January 21, 2015

EyewireTV — Victus Upgrades, Eidon US Launch

In this week's EyewireTV, Bausch + Lomb receives FDA 510(k) clearance for an advanced swept-source OCT imaging system and updated software for its Victus Femtosecond Laser Platform, and at the Royal Hawaiian Eye Meeting in Maui, CenterVue announces the US launch of the Eidon imaging system. Also, InnFocus provides updates on its MicroShunt glaucoma drainage implant. (1566 Views)

Watch Video

Wednesday, January 14, 2015

EyewireTV — New Postoperative Drop Formulation, 5-Year Cataract Surgery Study

In this week's EyewireTV, Imprimis Pharmaceuticals plans to introduce LessDrops, a proprietary eye drop formulation to be administered following laser refractive and cataract surgery; and a large, 5-year study examining trends in cataract surgery shows decreasing visual thresholds for surgery, decreasing surgical complication rates, and increasing visual outcomes. Also, Synergetics USA acquires Sterimedix, a provider of single-use ophthalmic instruments, in a deal worth up to $13.5 million. (2286 Views)

Watch Video

Wednesday, January 07, 2015

EyewireTV — 2014 FDA Drug Approvals, Digital Eye Strain

In this week's EyewireTV, the FDA’s drug approval rate hit an 18-year high in 2014 as the agency gave the green light to 44 new medicines; and new research shows that nearly 95% of Americans spend 2 or more hours every day on digital devices, highlighting the need to address the rising occurrence of eye strain. Also, Nidek announces the launch of the Retina Scan Duo, a device that combines high-definition OCT and fundus camera capabilities. (1680 Views)

Watch Video

Wednesday, December 31, 2014

EyewireTV — 2014 Year in Review

In this week's EyewireTV, a look back at some of EyewireTV’s most significant stories from 2014. It was an active year in ophthalmology, marked by mergers and acquisitions, landmark studies, new indications for well-known retina agents, and technology advancements across all areas of eye care. The year also included an aggressive and high-profile hostile takeover attempt. (1822 Views)

Watch Video

Tuesday, December 23, 2014

EyewireTV — Ophthalmic Leaders Provide Pipeline Updates

In this week's EyewireTV, several executives at the Ophthalmology Innovation Summit speak to EyewireTV about the main product candidates in their companies' pipeline. (1970 Views)

Watch Video

Wednesday, December 17, 2014

EyewireTV—AREDS Ocular Vitamins Study, Lucentis Designation for DR

In this week's EyewireTV, a study evaluating the top-selling ocular nutritional supplements finds that they contain the same ingredients as the AREDS and AREADS2 formulas, but not all contained the recommended doses; and the FDA grants breakthrough therapy designation for Lucentis (ranibizumab) for the treatment of diabetic retinopathy. Also, Shire provides updates on several products in its ophthalmic pipeline, including SHP607 for the prevention of retinopathy of prematurity, and lifitegrast for the treatment of dry eye disease. (2083 Views)

Watch Video

Wednesday, December 10, 2014

EyewireTV — Rhopressa Phase 3 Trial, Dropless Cataract Surgery

In this week’s EyewireTV, Aerie Pharmaceuticals completes enrollment in the 400-patient phase 3 clinical trial of glaucoma drug candidate Rhopressa; and CenterVue announces FDA 510(k) clearance for its Eidon true-color confocal scanner. In the feature, three ophthalmologists share their thoughts on providing anti-inflammatory and anti-bacterial agents during cataract surgery. (2435 Views)

Watch Video

Wednesday, December 03, 2014

EyewireTV — New Eylea Indication Review, Vitrectomy Reimbursement Cuts

In this week's EyewireTV, the FDA grants priority review for Eylea (aflibercept) for the treatment of diabetic retinopathy in patients with diabetic macular edema; and i-Optics announces the commercial launch of the Cassini Total Corneal Astigmatism functionality, which is designed to measure both anterior and posterior astigmatism. Also, the Centers for Medicare and Medicaid Services unveils reimbursement cuts for vitrectomy procedures starting in 2015. (2202 Views)

Watch Video

Tuesday, November 25, 2014

EyewireTV — Actavis and Allergan CEOs Reaction, First MillennialEYE Live

In this week's EyewireTV, days after Actavis announced it will acquire Allergan in a cash and stock deal worth $66 billion, Actavis President and CEO Brent Saunders, and Allergan Chairman and CEO David Pyott, speak with EyewireTV about the deal; and several young leaders in ophthalmology discuss the most important takeaway messages from the inaugural MillennialEYE Live, an innovative meeting hosted by Bryn Mawr Communications' digital publication, MillennialEYE, in Austin, Texas. (3226 Views)

Watch Video

Wednesday, November 19, 2014

EyewireTV —Actavis Buys Allergan, Valeant Buys Nicox, Vision for Mars Update

In this week's EyewireTV, in a blockbuster deal that will likely thwart a long and aggressive hostile takeover bid by Valeant, Actavis agrees to acquire Allergan for $66 billion in cash and stock; and Valeant acquires Nicox’s US diagnostics business, Nicox Inc., in a deal worth up to $20 million. Also, a team of researchers, NASA scientists, leading ophthalmologists, and business representatives, collectively known as the Vision for Mars team, makes several recommendations regarding various eye conditions in astronauts. (2534 Views)

Watch Video

Wednesday, November 12, 2014

EyewireTV — Allergan-Actavis Discussions, Phase 3 Dry Eye Study

In this week's EyewireTV, new reports emerge that Allergan is in talks with generic and specialty drugmaker Actavis about a possible takeover deal; and Eleven Biotherapeutics completes patient enrollment in its first phase 3 clinical study of EBI-005, its lead product candidate for dry eye disease. In the feature, three leading ophthalmologists discuss the advantages of having an integrated care model in their practice. (3541 Views)

Watch Video

Wednesday, November 05, 2014

EyewireTV — NASA Eye Health, Omidria CMS Pass-Through

In this week's EyewireTV, a new public-private partnership led by a NASA entity is formed with the task of safeguarding the eye during and after long-duration space travel; and Omeros receives transitional pass-through status from the Centers for Medicare & Medicaid Services for its lead product Omidria. Also, new research shows that the severity of AMD in one eye is associated with the incidence and progression of AMD in the other eye. (2371 Views)

Watch Video
Load More